+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023 - Product Image

Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023

  • ID: 4749693
  • Report
  • January 2019
  • Region: Global
  • 118 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Teva Pharmaceutical
  • MORE
COPD is a chronic non-communicable, lifestyle-related disease, which progresses continuously in the absence of medical intervention. There are several lifestyle-related factors such as smoking, exposure to biomass fuel, and air pollution, which increase the risk of developing COPD. In addition to tobacco smoke, there are other factors such as occupational exposure, outdoor pollution, exposure to second-hand or passive smoking, smoke from the burning of biomass, respiratory infections, poor nutritional status, chronic asthma, impaired lung growth, poor socio-economic status and dietary factors, which lead directly or indirectly to COPD. Apart from lifestyle factors, there are factors such as old age and presence of rare genetic disorders, which contribute to the rising prevalence of COPD. The analysts have predicted that the chronic obstructive pulmonary disease (COPD) drugs market will register a CAGR of almost 4% by 2023.

Market Overview

Strong pipeline and new drug approvals

The pipeline for the treatment of COPD includes several drug combinations, which can provide a wide range of therapeutic benefits. These drug combinations are presently in the late stages of development, with some expected to be launched in the market during the forecast period. These molecules combine the properties of drugs from different classes and have diversified therapeutic mechanisms of action and hence are expected to change the course of COPD treatment.

Low diagnosis rates for COPD

There is a lack of knowledge and awareness about COPD especially in the developing countries due to which primary care practitioners (PCPs) and other healthcare providers delay or incorrectly diagnose COPD. Another major factor contributing to the poor diagnosis of COPD is the diagnostic confusion between COPD and asthma. Thus, poor or incorrect diagnosis is a major challenge as it prevents people with COPD from getting a proper diagnosis which, in turn, has a negative impact on market growth.

For the detailed list of factors that will drive and challenge the growth of the chronic obstructive pulmonary disease (COPD) drugs market during the 2019-2023, view this report.

Competitive Landscape

The chronic obstructive pulmonary disease (COPD) drugs market appears to be moderately concentrated and with the presence of few companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Teva Pharmaceutical
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Combination therapy - Market size and forecast 2018-2023
  • Monotherapy - Market size and forecast 2018-2023
  • Market opportunity by product
PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE
  • Chronic bronchitis
  • Emphysema
PART 10: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Teva Pharmaceutical
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global respiratory disorder drugs market
Exhibit 03: Segments of global respiratory disorder drugs market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Pipeline molecules for COPD
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2018
Exhibit 19: Product - Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: Combination therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Combination therapy - Year-over-year growth 2019-2023 (%)
Exhibit 23: Monotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Monotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 25: Sales of monotherapy drugs 2015-2017 ($ millions)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Decision framework
Exhibit 41: Mechanism of action of budesonide/ glycopyrronium/formoterol triple combination
Exhibit 42: New drug approvals for COPD
Exhibit 43: US FDA-approved fixed-dose combination LABAs and LAMAs
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Examples of advanced nebulizers
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: AstraZeneca - Vendor overview
Exhibit 52: AstraZeneca - Business segments
Exhibit 53: AstraZeneca - Organizational developments
Exhibit 54: AstraZeneca - Geographic focus
Exhibit 55: AstraZeneca - Key offerings
Exhibit 56: Boehringer Ingelheim - Vendor overview
Exhibit 57: Boehringer Ingelheim - Business segments
Exhibit 58: Boehringer Ingelheim - Organizational developments
Exhibit 59: Boehringer Ingelheim - Geographic focus
Exhibit 60: Boehringer Ingelheim - Segment focus
Exhibit 61: Boehringer Ingelheim - Key offerings
Exhibit 62: GlaxoSmithKline - Vendor overview
Exhibit 63: GlaxoSmithKline - Business segments
Exhibit 64: GlaxoSmithKline - Organizational developments
Exhibit 65: GlaxoSmithKline - Geographic focus
Exhibit 66: GlaxoSmithKline - Segment focus
Exhibit 67: GlaxoSmithKline - Key offerings
Exhibit 68: Novartis - Vendor overview
Exhibit 69: Novartis - Business segments
Exhibit 70: Novartis - Organizational developments
Exhibit 71: Novartis - Geographic focus
Exhibit 72: Novartis - Segment focus
Exhibit 73: Novartis - Key offerings
Exhibit 74: Teva Pharmaceutical - Vendor overview
Exhibit 75: Teva Pharmaceutical - Business segments
Exhibit 76: Teva Pharmaceutical - Organizational developments
Exhibit 77: Teva Pharmaceutical - Geographic focus
Exhibit 78: Teva Pharmaceutical - Segment focus
Exhibit 79: Teva Pharmaceutical - Key offerings
Exhibit 80: Validation techniques employed for market sizing
Exhibit 81: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Teva Pharmaceutical
  • MORE
Global Chronic Obstructive Pulmonary Disease (COPD) Drugs Market 2019-2023

The analyst recognizes the following companies as the key players in the global chronic obstructive pulmonary disease (COPD) drugs market: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Teva Pharmaceutical.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the growing use of e-cigarettes and other products for people to quit smoking.”

According to the report, one of the major drivers for this market is the growing demand for fixed-dose combinations.

Further, the report states that one of the major factors hindering the growth of this market is failures of monoclonal antibodies for the treatment of COPD.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AstraZeneca
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Teva Pharmaceutical
Note: Product cover images may vary from those shown
Adroll
adroll